Statement Of Cash Flows [Abstract]

Innate Pharma - Filing #5981200

Concept 2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Adjustments for finance income
EUR
991,000 EUR
Cash flows from (used in) operations before changes in working capital
46 058 EUR
467,000 EUR
Increase (decrease) in working capital
39 162 EUR
32 092 EUR
Adjustments for decrease (increase) in trade and other receivables
51 811 EUR
13 666 EUR
Adjustments for increase (decrease) in trade and other payables
1 011 EUR
3 893 EUR
Adjustments for increase (decrease) in deferred income including contract liabilities [abstract]
Adjustments for increase (decrease) in deferred income including contract liabilities
7 042 EUR
3 998 EUR
Adjustments for increase (decrease) in employee benefit liabilities
324,000 EUR
285,000 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.